Cisco beats earnings estimates, reports strong revenue and raises guidance, leading to positive ratings and price target increases from analysts. Latest Ratings for CSCO Date Firm Action From To Mar 2022 Wells Fargo Downgrades Overweight Equal-Weight Feb 2022 Cowen & Co. Maintains Outperform Feb 2022 Raymond James Maintains Outperform View More Analyst Ratings for CSCO…
Oppenheimer analyst Brian Bittner maintains an Outperform rating on Restaurant Brands with a $77 price target. Analyst projects a 2.5% same-store sales growth for 2025, slightly under the company’s target, with unit growth forecasted at 3.6%. Latest Ratings for QSR Date Firm Action From To Feb 2022 Stephens & Co. Maintains Equal-Weight Jan 2022 Morgan…
Latest Ratings for GTLS Date Firm Action From To Mar 2022 B of A Securities Upgrades Neutral Buy Mar 2022 Barclays Maintains Overweight Feb 2022 Wells Fargo Maintains Overweight View More Analyst Ratings for GTLS View the Latest Analyst Ratings read more
Latest Ratings for ADBE Date Firm Action From To Mar 2022 Mizuho Maintains Buy Jan 2022 Deutsche Bank Maintains Buy Jan 2022 UBS Downgrades Buy Neutral View More Analyst Ratings for ADBE View the Latest Analyst Ratings read more
Latest Ratings for AR Date Firm Action From To Feb 2022 Raymond James Maintains Strong Buy Jan 2022 Morgan Stanley Maintains Equal-Weight Jan 2022 Goldman Sachs Upgrades Neutral Buy View More Analyst Ratings for AR View the Latest Analyst Ratings read more
Latest Ratings for GDDY Date Firm Action From To Feb 2022 Morgan Stanley Maintains Equal-Weight Feb 2022 Piper Sandler Maintains Neutral Feb 2022 Raymond James Maintains Strong Buy View More Analyst Ratings for GDDY View the Latest Analyst Ratings read more
GE HealthCare Q4 earnings beat estimates with strong U.S. demand. 2025 outlook includes 2%-3% revenue growth and EPS guidance of $4.61-$4.75. read more
Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in late 2025, with another in 2026. read more